KYNTRA BIO, INC. — Form 8-K
Filed August 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., reducing maximum aggregate payments from $125M to $65M. The company made a $42.6M upfront payment (bringing total paid to $50M, fully returning the investor's capital), with remaining obligations capped at $15M paid from 50% of Astellas EVRENZO revenues. Pro forma cash position: $53.1M as of June 30, 2026, extending runway to Q4 2027.
Why this rating
Material deleveraging ($60M liability reduction, 286% of company market cap) materially improves financial position and extends runway to key clinical readouts in late 2026–2027.
Price action (we called it positive)
before filing · preread $7.65 ▼ 1.67% | at our read · unknown $7.78 | +10 min · unknown $7.78 ▲ 0.00% | +30 min · unknown $7.78 ▲ 0.00% | +1 hr · unknown $7.78 ▲ 0.00% | +4 hrs pending |
The stock had already moved +1.70% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.